The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer's disease -- despite an FDA advisory committee concluding last year ...

The FDA approved the drug despite a "no" vote from its advisory committee, whose members felt the medicine did little to ...

The Alzheimer’s disease market has achieved a groundbreaking milestone with the FDA approval of LEQEMBI IQLIK (lecanemab-irmb ...

CAMBRIDGE, Mass. -- Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of ...

The anti-amyloid maintenance therapy offers a once-weekly, subcutaneous option after 18 months of intravenous treatment.